Related Experiment Video
Updated: May 13, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Gene polymorphism in amlodipine induced gingival hyperplasia: a case report
Nsc Charles1, V Ramesh, Kennedy Spk Babu
1Department of Oral Pathology and Microbiology, Mahatma Gandhi Postgraduate Institute of Dental Sciences, Indira Nagar, Gorimedu, Puducherry, India.
Journal of Young Pharmacists : JYP
|March 16, 2013
Summary
Amlodipine, a common cardiovascular drug, can cause gingival overgrowth. This review discusses its oral side effects and the mechanisms behind this adverse reaction.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Oral Medicine
Background:
- Cardiovascular disorders require effective management, often involving Calcium Channel Blockers (CCBs).
- Gingival overgrowth is a known adverse effect associated with CCBs.
- Amlodipine, a widely used CCB for hypertension, has demonstrated significant effects on gingival tissues.
Purpose of the Study:
- To raise awareness about the adverse oral effects of amlodipine.
- To elucidate the mechanism of action responsible for amlodipine-induced gingival overgrowth.
- To provide a concise review of amlodipine's pharmacologic profile.
Main Methods:
- Literature review of amlodipine's effects on gingival tissues.
- Analysis of proposed mechanisms for drug-induced gingival overgrowth.
- Pharmacological profile summary of amlodipine.
Main Results:
- Amlodipine, despite its therapeutic benefits, is associated with gingival overgrowth.
- Potential mechanisms involve altered fibroblast function and inflammatory responses.
- Understanding these effects is crucial for patient and dental professional management.
Conclusions:
- Amlodipine use necessitates awareness of potential gingival overgrowth.
- Further research into the precise mechanisms is warranted.
- Interdisciplinary communication between physicians and dentists is vital for patient care.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...